# IMpower132 (NCT02657434)

> A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)

No report yet. It can be ordered.

- Drugs tested: atezolizumab
- Indication: chemotherapy-naive stage IV non-squamous NSCLC

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02657434
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Non-Small Cell Lung Cancer
- Interventions: Atezolizumab; Carboplatin; Cisplatin; Pemetrexed
- Enrollment: 578
- Primary outcome: Progression Free Survival (PFS) as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
- Primary outcome: Overall Survival (OS)

## Indexed commentary on IMpower132 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 15
- Podcasts: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=impower132-nct02657434

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02657434", "email": "<work email>"}; the inbox owner confirms by the emailed link.